TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding TScan Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Of which not filed for Q4 2025 | Q4 2025 | Change |
|---|---|---|---|---|
| Holders | 73 | 2 | 61 | −10 |
| Shares | 34.6M | 56.6K | 30.7M | −3.85M (−11.1%) |
| Value | $62.9M | $103.0K | $30.7M | −$32.1M (−51.1%) |
2 institutions that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held TScan Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 226,164 | $226.0K | 0.02% |
| Jacobs Levy Equity Management, Inc | 188,152 | $188.2K | 0.00% |
| D. E. Shaw & Co., Inc. | 69,427 | $69.4K | 0.00% |
| Acadian Asset Management LLC | 29,538 | $28.0K | 0.00% |
| HRT Financial LP | 26,581 | $26.0K | 0.00% |
| Panagora Asset Management Inc | 25,256 | $25.3K | 0.00% |
| Two Sigma Securities, LLC | 15,942 | $15.9K | 0.00% |
| Point72 Asset Management, L.P. | 14,512 | $14.5K | 0.00% |
| Mizuho Securities USA LLC | 10,000 | $10.1K | 0.00% |
| Northwestern Mutual Wealth Management Co | 8 | $8 | 0.00% |
Sold out (20)
Institutions that held TScan Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Propel Bio Management, LLC | 1,932,304 | $3.52M |
| Alphabet Inc. | 1,077,080 | $1.96M |
| Simplify Asset Management Inc. | 904,972 | $1.65M |
| Militia Capital Partners, LP | 102,100 | $185.8K |
| Virtu Financial LLC | 60,480 | $110.0K |
| Quadrature Capital Ltd | 56,666 | $103.4K |
| Voleon Capital Management LP | 47,879 | $87.1K |
| Catalyst Funds Management Pty Ltd | 30,763 | $56.0K |
| Algert Global LLC | 28,030 | $51.0K |
| Qube Research & Technologies Ltd | 27,675 | $50.4K |
| Mariner, LLC | 16,031 | $29.2K |
| China Universal Asset Management Co., Ltd. | 9,197 | $16.7K |
| Mirae Asset Global Investments Co., Ltd. | 2,029 | $3.69K |
| Citigroup Inc | 1,088 | $1.98K |
| GF Fund Management Co. Ltd. | 1,020 | $1.86K |
| Nisa Investment Advisors, LLC | 593 | $1.08K |
| Rialto Wealth Management, LLC | 381 | $694 |
| EverSource Wealth Advisors, LLC | 65 | $118 |
| True Wealth Design, LLC | 9 | $17 |
| CWM, LLC | 8 | $0 |
Not filed for Q4 2025 yet (2)
Institutions that held TScan Therapeutics, Inc. at the end of Q3 2025 and haven't filed a 13F for Q4 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Cubist Systematic Strategies, LLC | 42,078 | $76.6K |
| Point72 Asia (Singapore) Pte. Ltd. | 14,535 | $26.5K |